Five-Year Outcomes with First-Line Nivolumab plus Ipilimumab plus Chemotherapy Versus Chemotherapy in Patients with Metastatic NSCLC (mNSCLC) in CheckMate 9LA
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Reck, Martin
- Ciuleanu, Tudor-Eliade
- Schenker, Michael
- Bordenave, Stephanie
- Cobo-Dols, Manuel
- Reinmuth, Niels
- Richardet, Eduardo
- Felip, Enriqueta
- Menezes, Juliana
- Cheng, Ying
- Mizutani, Hideaki
- Carbone, David P.
- Lu, Shun
- John, Thomas
- Aoyama, Takekazu
- Mahmood, Javed
- Hu, Nan
- Eccles, Laura
- Paz-Ares, Luis G.
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Cita
Reck,M,Ciuleanu,T,Schenker,M,Bordenave,S,Cobo,M,Juan,O,Reinmuth,N et al. Five-Year Outcomes with First-Line Nivolumab plus Ipilimumab plus Chemotherapy Versus Chemotherapy in Patients with Metastatic NSCLC (mNSCLC) in CheckMate 9LA. STE 800, 230 PARK AVE, NEW YORK, NY 10169:ELSEVIER SCIENCE INC. 2025.
Portal de investigación